Treatment of high numbers of brain metastases with Gamma Knife radiosurgery: a review

Effectiveness of stereotactic radiosurgery (SRS) has been shown in patients with one to four brain metastases. Work has been done to evaluate the role of SRS alone treatment without whole-brain radiation therapy in patients with more than four metastases. A recent multiinstitutional JLGK 0901 prospe...

Full description

Saved in:
Bibliographic Details
Published in:Acta Neurochirurgica 2016-04, Vol.158 (4), p.625-634
Main Authors: Hatiboglu, Mustafa Aziz, Tuzgen, Saffet, Akdur, Kerime, Chang, Eric L.
Format: Article
Language:English
Subjects:
Brain Neoplasms - pathology
Brain Neoplasms - radiotherapy
Humans
Interventional Radiology
Medicine
Medicine & Public Health
Minimally Invasive Surgery
Neoplasm Metastasis
Neurology
Neuroradiology
Neurosurgery
Radiosurgery - adverse effects
Radiosurgery - methods
Review Article - Brain Tumors
Surgical Orthopedics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Effectiveness of stereotactic radiosurgery (SRS) has been shown in patients with one to four brain metastases. Work has been done to evaluate the role of SRS alone treatment without whole-brain radiation therapy in patients with more than four metastases. A recent multiinstitutional JLGK 0901 prospective study revealed the class-2 evidence that SRS without whole-brain radiation therapy is an effective treatment for patients up to 10 metastatic lesions. Several retrospective studies exist to show the efficacy and safety of SRS for patients with even more than 10 lesions. However, patient selection is very critical for SRS alone treatment. The PubMed database was searched using combinations of search terms and synonyms for multiple brain metastases, Gamma Knife and SRS published between January 1, 2005 and January 1, 2015 in order to address the effectiveness of Gamma Knife for patients with multiple brain metastases. Good performance status, controlled primary disease, total treated tumor volume of 15 cm 3 or less have been found to be significant predictors for survival among patients with two or more brain lesions. The data suggest that SRS can be used and whole brain radiation therapy can be withheld in selected patients with multiple lesions to avoid acute or chronic adverse effects, especially neurocognitive decline, without causing survival disadvantage. In this review, we assessed the evidence for SRS treatment of patients with multiple brain metastases.
ISSN:0001-6268
0942-0940
DOI:10.1007/s00701-016-2707-6